CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Selling, general and administrative	$ 4,649	$ 3,841
Research and development	5,732	9,205
Change in fair value of contingent consideration	63,769
Total operating costs and expenses	74,150	13,046
Loss from operations	(74,150)	(13,046)
Other (loss) income:
Change in fair value of convertible notes	(87)	(4,657)
Change in fair value of warrants	(20,903)
Loss on embedded forward purchase agreements and derivative liabilities, net	(22,917)
Other income, net	39	64
Total other loss, net	(43,868)	(4,593)
Loss before taxes	(118,018)	(17,639)
Net loss and comprehensive loss	$ (118,018)	$ (17,639)
Basic net loss per share (in dollars per share)	$ (3.17)	$ (0.13)
Diluted net loss per share (in dollars per share)	$ (3.17)	$ (0.13)
Weighted average shares of common stock outstanding used to compute basic net loss per share	37,268,074	138,825,356
Weighted average shares of common stock outstanding used to compute diluted net loss per share	37,268,074	138,825,356
Financial Designation, Predecessor and Successor [Fixed List]	Successor	Predecessor